Does Rallies show 13F holders for INMB?

Yes. Rallies tracks hedge fund and 13F ownership data for INMB, including fund names, share counts, latest tracked quarter, and position changes when available.

Is INMB research on Rallies investment advice?

No. Rallies provides research, data, and educational context for INMB. It does not provide personalized investment advice.

INMB (INmune Bio Inc. Common stock) Stock Analysis - Hedge Fund Holdings

INmune Bio Inc. Common stock (INMB) is a publicly traded Healthcare sector company. As of May 21, 2026, INMB trades at $1.45 with a market cap of $39.61M and a P/E ratio of -0.75. INMB moved -0.71% today. Year to date, INMB is -5.37%; over the trailing twelve months it is -81.64%. Its 52-week range spans $1.09 to $11.64. Analyst consensus is strong buy with an average price target of $8.00. Rallies surfaces INMB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns INMB stock?

Hedge funds tracked by Rallies that own INMB include Sculptor Capital. The latest tracked quarter is Sep 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for INmune Bio Inc. Common stock.

INMB Key Metrics

Key financial metrics for INMB
Metric	Value
Price	$1.45
Market Cap	$39.61M
P/E Ratio	-0.75
EPS	$-1.86
Dividend Yield	0.00%
52-Week High	$11.64
52-Week Low	$1.09
Volume	539
Avg Volume	0
Revenue (TTM)	$50.00K
Net Income	$-45.93M
Gross Margin	0.00%

Top Hedge Funds Holding INMB

Sculptor Capital holds 6.10K shares of INMB, changed -41.35% as of Sep 30, 2025.

Latest INMB News

INmune Bio Expands CORDStrom Collaboration with Anthony Nolan, Securing Long-Term Cord Supply for RDEB, Oncology and Inflammation — May 5, 2026
INmune Bio Impairs $16.5M Asset, Completes Prostate Cancer Trial Under Budget — Mar 31, 2026
INmune Bio Raises $27.5M, Targets Mid-Summer UK MAA Filing for CORDStrom Therapy — Mar 30, 2026
INmune Bio Schedules Feb 26 Webinar to Unveil Phase III RDEB CORDStrom Data — Feb 19, 2026
INmune Bio Files MHRA Pre-Submission Package for CORDStrom Program — Feb 11, 2026

Recent INMB Insider Trades

Moss David J bought 10.00K (~$52.87K) on Sep 30, 2024.
Tesi Raymond Joseph bought 15.38K (~$98.05K) on Sep 12, 2024.
Moss David J bought 7.69K (~$49.02K) on Sep 12, 2024.

INMB Analyst Consensus

3 analysts cover INMB: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $8.00.

Common questions about INMB

Who owns INMB stock?: Hedge funds tracked by Rallies that own INMB include Sculptor Capital. The latest tracked quarter is Sep 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for INmune Bio Inc. Common stock.
Does Rallies show 13F holders for INMB?: Yes. Rallies tracks hedge fund and 13F ownership data for INMB, including fund names, share counts, latest tracked quarter, and position changes when available.
Is INMB research on Rallies investment advice?: No. Rallies provides research, data, and educational context for INMB. It does not provide personalized investment advice.